|
EQS-News: BRAIN Biotech AG
/ Key word(s): Miscellaneous
MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG
Zwingenberg, November 17, 2022 – BRAIN Biotech AG was informed by its anchor investor MP Beteiligungs-GmbH, Kaiserslautern, that MP Beteiligungs-GmbH now holds approximately 45 percent of the total share capital in BRAIN Biotech AG. The shareholding of MP Beteiligungs-GmbH in BRAIN Biotech AG has been continuously expanded over the course of the year through acquisitions in the open market. Due to the completion of a recent major block transaction, the total shareholding has grown to approximately 45%. MP Beteiligungs-GmbH intends to continue to accompany the development of BRAIN Biotech AG on the capital market in the long-term and considers the currently weak capital market environment for the BRAIN Biotech AG share price as a good investment opportunity. Adriaan Moelker, CEO BRAIN Biotech, states: "We are very pleased with the continued vote of confidence from our anchor investor MP Beteiligungs-GmbH. BRAIN Biotech is developing very positively, both operationally as well as strategically. We are well on track to achieve our goals for this year and the medium term."
About BRAIN BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology with a focus on nutrition, health and the environment. As a technology and solution provider, the company supports the biologization of industry with biobased products and processes. From contract research and development with industrial partners to the development of own disruptive incubator projects and customized enzyme products: BRAIN's broad, innovative biotech know-how and its agile teams are the key to success. The German BRAIN Biotech AG is the parent company of the international BRAIN Group, which distributes B2B specialty products, including enzymes and bioactive natural products. The BRAIN Group has its own fermentation or production facilities in continental Europe, the UK and the USA, which complete the value chain within the Group with the associated biotechnological production know-how. As a participant in the United Nations Global Compact, BRAIN Biotech AG is committed to aligning its strategies and activities with the universal principles on human rights, labor, environment and anti-corruption, and to actively promote common social goals. Our products and services directly target at least five of the UN SDGs. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Contact Investor Relations
Contact media
Follow @BRAINbiotech on Twitter (https://twitter.com/BRAINbiotech) and on LinkedIn (https://www.linkedin.com/company/brainbiotech)
Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations and assumptions of the management of BRAIN Biotech AG and are based on information currently available to management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties. The actual future results of BRAIN Biotech AG and the BRAIN Group and developments concerning BRAIN Biotech AG and the BRAIN Group may therefore differ materially from the expectations and assumptions expressed herein due to various factors. These factors include, in particular, changes in the general economic situation and the competitive situation. In addition, developments on the financial markets and exchange rate fluctuations, as well as national and international legislative changes, particularly with regard to tax regulations, and other factors may have an impact on the future results and developments of BRAIN Biotech AG. BRAIN Biotech AG assumes no obligation to update the statements contained in this release.
17.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1490093 |
| End of News | EQS News Service |
|
|
1490093 17.11.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
Special
